001484360 000__ 04421cam\\2200589\i\4500
001484360 001__ 1484360
001484360 003__ OCoLC
001484360 005__ 20240117003322.0
001484360 006__ m\\\\\o\\d\\\\\\\\
001484360 007__ cr\cn\nnnunnun
001484360 008__ 231128s2023\\\\sz\a\\\\o\\\\\000\0\eng\d
001484360 019__ $$a1410333345$$a1410333614$$a1410591463
001484360 020__ $$a9783031300653$$q(electronic bk.)
001484360 020__ $$a3031300653$$q(electronic bk.)
001484360 020__ $$z3031300645
001484360 020__ $$z9783031300646
001484360 0247_ $$a10.1007/978-3-031-30065-3$$2doi
001484360 035__ $$aSP(OCoLC)1410824707
001484360 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dOCLCO$$dEBLCP$$dYDX$$dOCLKB
001484360 049__ $$aISEA
001484360 050_4 $$aRC270.8
001484360 08204 $$a616.99406$$223/eng/20231128
001484360 24500 $$aTargeting the DNA damage response for cancer therapy /$$cTimothy A. Yap, Geoffrey I. Shapiro, editors.
001484360 264_1 $$aCham :$$bSpringer,$$c2023.
001484360 300__ $$a1 online resource (420 pages) :$$billustrations (black and white, and color).
001484360 336__ $$atext$$btxt$$2rdacontent
001484360 337__ $$acomputer$$bc$$2rdamedia
001484360 338__ $$aonline resource$$bcr$$2rdacarrier
001484360 4901_ $$aCancer treatment and research ;$$vvolume 186
001484360 5050_ $$aEvolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).
001484360 506__ $$aAccess limited to authorized users.
001484360 520__ $$aThis book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.
001484360 588__ $$aDescription based on print version record.
001484360 650_6 $$aCancer$$xTraitement.
001484360 650_6 $$aADN$$xLésions.
001484360 650_6 $$aADN$$xRéparation.
001484360 650_0 $$aCancer$$xTreatment.$$0(DLC)sh2006006447
001484360 650_0 $$aDNA damage.
001484360 650_0 $$aDNA repair.
001484360 655_0 $$aElectronic books.
001484360 7001_ $$aYap, Timothy A.,$$eeditor.
001484360 7001_ $$aShapiro, Geoffrey I.$$eeditor.
001484360 77608 $$iPrint version:$$tTARGETING THE DNA DAMAGE RESPONSE FOR CANCER THERAPY.$$d[Place of publication not identified] : SPRINGER INTERNATIONAL PU, 2023$$z3031300645$$w(OCoLC)1372132975
001484360 830_0 $$aCancer treatment and research ;$$vv. 186.
001484360 852__ $$bebk
001484360 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-30065-3$$zOnline Access$$91397441.1
001484360 909CO $$ooai:library.usi.edu:1484360$$pGLOBAL_SET
001484360 980__ $$aBIB
001484360 980__ $$aEBOOK
001484360 982__ $$aEbook
001484360 983__ $$aOnline
001484360 994__ $$a92$$bISE